Psoriatic Arthritis

At the 2022 Fall Clinical Dermatology Conference, Bruce E. Strober, MD, PhD, reviewed the best treatment options for patients with psoriasis and psoriatic arthritis.

Two expert dermatologists discuss the relationship between PsA and PsO in this DermView series recap.

Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.

Arthur Kavanaugh, MD, a professor of medicine and director of the Center for Innovative Therapy (CIT) at UC San Diego in California, gives his thoughts on the treatments for psoriatic arthritis, the comorbidities that have to be considered, and more.

Arthur Kavanaugh, MD, a professor of medicine and director of the Center for Innovative Therapy (CIT) at UC San Diego in California, gives his thoughts on the future of psoriatic arthritis.

At the SDPA 2022 Annual Summer Dermatology Conference, a session on both common and rare dermatological disorders.

Tralokinumab-ldrm (Adbry; LEO Pharma) showed improvement in itch, sleep, anxiety, depression, and overall quality of life data for adolescent AD patients in newly released study data.

AbbVie announced the FDA approval to their IL-23 inhibitor risankizumab-rzaa (Skyrizi) for treatment of active psoriatic arthritis (PsA) in adult patients based on the results of the KEEPsAKE-1 and KEEPsAKE-2 trials.

Secukinumab is the only biologic treatment in the US that’s approved by the FDA for pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).

A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.